Loading
A phase 3 trial of Iomab-B run by Actinium Pharmaceuticals, active.
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT02665065 by Actinium Pharmaceuticals, with 153 participants enrolled, started 2016-06. Conditions listed: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Actinium Pharmaceuticals, Radio-antibody & radio-ADC, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/